aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a potential first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 80 issued or allowed patents and over 230 pending patent applications that are owned or exclusively licensed by aTyr, including over 300 potential Physiocrine-based protein compositions. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options.
Educational Webinar on Interstitial Lung Disease and aTyr’s iMod.Fc Program at the American Thoracic Society International CongressMay 23, 2017 8:30 AM EDTOn Tuesday, May 23, 2017 at 8:30 a.m. ET, aTyr Pharma will host a conference call and webcast with an accompanying slide presentation to discuss interstitial lung disease and the iMod.Fc program. Joining the aTyr Pharma management will be Steven D. Nathan, M.D., FCCP, Director of the Advanced Lung Disease Program and Medical Director of the Lung Transplant Program at Inova Fairfax Hospital. To access the call, please dial 844-358-9116 (domestic) or 209-905-5951 (international) and ask to join the aTyr Pharma call.